Trials / Terminated
TerminatedNCT00473616
Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan
A Phase I Open-label, Multi-center, Dose-escalation and Safety Expansion Study to Assess Safety, Tolerability, and Pharmacokinectics of AZD7762 Administered as a Single Intravenous Agent and in Combination With Weekly Standard Dose of Irinotecan in Patients With Advanced Solid Malignancies.
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multi-center, dose-escalation and safety expansion, Phase I study to evaluate the safety, tolerability, and pharmacokinectics and to investigate biomarker changes of AZD7762 administered as a single intravenous unit and in combination with irinotecan. The study is sponsored by AstraZeneca.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD7762 | intravenous infusion |
| DRUG | Irinotecan | intravenous injection |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2011-01-01
- Completion
- 2011-01-01
- First posted
- 2007-05-15
- Last updated
- 2011-02-11
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00473616. Inclusion in this directory is not an endorsement.